Skip to main content

Biogen income statement

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

Biogen reported revenue of $9.89 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 2.2% from fiscal 2024. Net income was $1.29 billion and diluted earnings per share $8.79.

From Biogen's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Biogen income statement, annual
USDFY 2007FY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$3.17B$4.10B$4.38B$4.72B$5.05B$5.52B$6.93B$9.70B$10.76B$11.45B$12.27B$13.45B$14.38B$13.44B$10.98B$10.17B$9.84B$9.68B$9.89B$10.30B
Revenue growth—+29.2%+6.8%+7.7%+7.0%+9.3%+25.7%+40.0%+10.9%+6.4%+7.2%+9.6%+6.9%−6.5%−18.3%−7.4%−3.3%−1.6%+2.2%—
Cost of revenue$335.2M$402.0M$382.1M$400.3M$466.8M$545.5M$857.7M$1.17B$1.24B$1.48B$1.63B$1.82B$1.96B$1.81B$2.11B$2.28B$2.53B$2.31B$2.40B$2.68B
Gross profit$2.84B$3.70B$4.00B$4.32B$4.58B$4.97B$6.07B$8.53B$9.52B$9.97B$10.64B$11.64B$12.42B$11.64B$8.87B$7.90B$7.30B$7.37B$7.49B$7.62B
Gross margin89.4%90.2%91.3%91.5%90.8%90.1%87.6%87.9%88.5%87.1%86.7%86.5%86.4%86.6%80.8%77.6%74.2%76.1%75.7%74.0%
Research and development$925.2M$1.07B$1.28B$1.25B$1.22B$1.33B——————————————
Selling, general and administrative$776.1M$925.3M$911.0M$1.03B$1.06B$1.28B$1.71B$2.23B$2.11B$1.95B$1.93B$2.11B$2.37B$2.50B$2.67B$2.40B$2.55B$2.40B$2.43B$2.75B
Operating income$779.8M$1.21B$1.30B$1.25B$1.72B$1.86B$2.52B$3.97B$4.89B$5.15B$5.35B$5.89B$7.04B$4.55B$2.84B$3.84B$1.61B$2.25B$1.86B$750.7M
Operating margin24.6%29.6%29.6%26.5%34.2%33.6%36.3%40.9%45.4%45.0%43.6%43.8%49.0%33.8%25.9%37.7%16.4%23.2%18.8%7.3%
Interest expense—$52.00M$35.80M$36.10M$33.00M$36.50M$31.90M$29.50M$95.50M$260.0M$250.8M$200.6M$187.4M$222.5M$253.6M$246.6M$246.9M$250.3M$267.5M$304.9M
Other income and expense————————−$123.7M−$218.7M−$217.0M$11.00M$83.30M$497.4M−$1.10B$108.2M−$315.5M−$343.6M−$305.6M—
Income before tax$852.2M$1.16B$1.33B$1.23B$1.71B$1.86B$2.48B$3.95B$4.77B$4.93B$5.13B$5.90B$7.13B$5.05B$1.75B$3.59B$1.30B$1.91B$1.56B$445.1M
Income tax expense$272.4M$365.8M$355.6M$331.3M$444.5M$470.6M$601.0M$989.9M$1.16B$1.24B$2.46B$1.43B$1.16B$992.3M$52.50M$632.8M$135.3M$273.8M$263.6M$97.60M
Effective tax rate32.0%31.6%26.7%26.9%26.0%25.4%24.2%25.1%24.4%25.1%47.9%24.2%16.3%19.7%3.0%17.6%10.4%14.4%16.9%21.9%
Net income$638.2M$783.2M$970.1M$1.01B$1.23B$1.38B$1.86B$2.93B$3.55B$3.70B$2.54B$4.43B$5.89B$4.00B$1.56B$3.05B$1.16B$1.63B$1.29B$347.5M
Net margin20.1%19.1%22.2%21.3%24.5%25.0%26.9%30.2%33.0%32.3%20.7%32.9%41.0%29.8%14.2%29.9%11.8%16.9%13.1%3.4%
Net income to common shareholders—$781.9M—$1.00B——$1.86B—————————————
EPS · diluted$1.99$2.65$3.35$3.94$5.04$5.76$7.81$12.37$15.34$16.93$11.92$21.58$31.42$24.80$10.40$20.87$7.97$11.18$8.79$2.34
Diluted weighted average shares320M295M289M255M245M240M238M237M231M219M213M205M187M161M150M146M146M146M147M148M
Basic weighted average shares316M292M287M252M242M238M237M236M231M218M213M205M187M161M149M145M145M146M147M147M
EBITDA$1.16B$1.68B$1.72B$1.60B$2.08B$2.22B$3.05B$4.66B$5.49B$5.83B$6.43B$6.54B$7.51B$5.01B$3.33B$4.36B$2.11B$2.92B$2.64B$1.63B
EBITDA margin36.6%40.9%39.4%34.0%41.3%40.3%44.0%48.0%51.0%51.0%52.4%48.6%52.2%37.2%30.3%42.8%21.4%30.2%26.7%15.9%
Depreciation & amortization$380.3M$462.1M$428.0M$355.7M$358.9M$365.6M$531.7M$688.1M$600.4M$682.7M$1.08B$650.5M$464.7M$457.2M$487.7M$518.4M$494.8M$673.2M$779.9M$881.8M
Stock-based compensation$123.1M$146.2M$160.9M$167.8M$113.0M$118.6M$136.3M$155.3M$161.4M−$138.1M$128.0M$157.5M$182.3M$198.3M$238.6M$254.1M$264.2M$291.2M$290.8M$302.5M

Quarterly

Biogen income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$2.39B$2.29B$2.46B$2.47B$2.45B$2.43B$2.65B$2.53B$2.28B$2.48B$2.74B$2.80B
Cost of revenue$618.3M$542.2M$546.0M$638.7M$583.5M$629.3M$605.0M$674.4M$495.5M$661.0M$776.9M$748.4M
Gross profit$1.77B$1.75B$1.92B$1.83B$1.87B$1.80B$2.04B$1.86B$1.78B$1.82B$1.96B$2.06B
Gross margin74.1%76.3%77.8%74.1%76.2%74.1%77.1%73.4%78.3%73.3%71.6%73.3%
Selling, general and administrative$608.5M$581.5M$553.8M$588.4M$680.0M$572.5M$583.8M$594.8M$682.5M$607.3M$709.7M$752.0M
Operating income$607.1M$464.8M$698.7M$451.0M$635.1M$311.2M$744.0M$557.3M$249.6M$377.7M$132.4M−$9.00M
Operating margin25.4%20.3%28.3%18.3%25.9%12.8%28.1%22.0%11.0%15.2%4.8%−0.3%
Interest expense$71.50M$69.20M$61.30M$59.80M$60.00M$60.00M$72.60M$67.40M$67.50M$67.60M$82.30M$87.50M
Income before tax$291.6M$464.8M$698.7M$451.0M$291.5M$311.2M$744.0M$557.3M−$56.00M$377.7M$132.4M−$9.00M
Income tax expense$42.70M$71.40M$115.1M$62.50M$24.80M$70.70M$109.2M$90.80M−$7.10M$58.20M$34.90M$11.60M
Effective tax rate14.6%15.4%16.5%13.9%8.5%22.7%14.7%16.3%12.7%15.4%26.4%−129%
Net income$249.7M$393.4M$583.6M$388.5M$266.7M$240.5M$634.8M$466.5M−$48.90M$319.5M$97.50M−$20.60M
Net margin10.5%17.2%23.7%15.8%10.9%9.9%24.0%18.4%−2.1%12.9%3.6%−0.7%
EPS · diluted$1.71$2.70$4.00$2.66$1.83$1.64$4.33$3.17−$0.33$2.15$0.66−$0.14
Diluted weighted average shares146M146M146M146M145M147M147M147M148M148M149M148M
Basic weighted average shares145M145M146M146M146M146M147M147M147M147M148M148M
EBITDA$747.2M$612.3M$857.5M$633.8M$819.1M$494.4M$938.3M$759.5M$449.8M$582.1M$368.5M$232.1M
EBITDA margin31.3%26.7%34.8%25.7%33.4%20.3%35.5%30.0%19.7%23.5%13.5%8.3%
Depreciation & amortization$140.1M$147.5M$158.8M$182.8M$184.0M$183.2M$194.3M$202.2M$200.2M$204.4M$236.1M$241.1M
Stock-based compensation$54.90M$72.80M$70.60M$72.70M$75.10M$81.00M$74.90M$75.30M$59.60M$84.00M$77.40M$81.50M

The main figures as JSON and plain text. See data and methodology.

BIIB in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.